Previous 10 | Next 10 |
Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 In July, further strengthened...
2023-07-25 11:56:09 ET Summary Janux Therapeutics, Inc. is a small company with a deal from Merck & Co., Inc. and some solid early data. They are loaded with cash and have a long runway. Janux Therapeutics generates considerable smart money interest. Janux Ther...
2023-07-24 10:09:58 ET Gainers: Armata Pharmaceuticals ( ARMP ) +19% . Janux Therapeutics ( JANX ) +11% . Amylyx Pharmaceuticals ( AMLX ) +8% . Coherus BioSciences ( CHRS ) +7% . Nuwellis ( NUWE ) +7% . Losers: Kodiak...
2023-07-17 08:59:08 ET Biopharmaceutical company Janux Therapeutics ( NASDAQ: JANX ) said on Monday that it has priced an ~$60M underwritten offering of 4.2M shares and pre-funded warrants to purchase 583.45K shares. The shares are being sold at $12.46 per share and the pre-fu...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers ...
2023-06-22 12:14:19 ET The major market averages trade significantly higher on the year as investors approach the halfway point of 2023. However, not every stock finds itself on easy street with some market participants shorting popular names. As a frame of reference, short interest ref...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
-First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -$316.9 million in cash and cash equivalents and short-term investments at end of first q...
2023-05-09 04:02:31 ET Summary Despite the recent rebound, US-listed biotech stocks valuations are still "down to earth" compared to the strong recovery from the Covid-19 crisis. Relatively low market valuations offer an opportunity to add to positions in biotechnology stocks with...
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
Janux Therapeutics Inc. Website:
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board me...
2024-06-12 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...